Roivant affiliate plans sale of 200,000 shares

Roivant Sciences Ltd. received a notice that affiliate Eric Venker plans to sell 200,000 common shares, expected to be issued from an option exercise granted on 04/20/2022, with a proposed sale date of 07/27/2026 on NASDAQ via wire settlement.

Rhea-AI Filing Summary

Roivant Sciences Ltd. received a notice that affiliate Eric Venker plans to sell 200,000 common shares, expected to be issued from an option exercise granted on 04/20/2022, with a proposed sale date of 07/27/2026 on NASDAQ via wire settlement.

The notice also lists sales during the prior three months: 200,000 common shares on 05/22/2026 for an aggregate value of 6,054,730.92 and another 200,000 common shares on 06/24/2026 for an aggregate value of 6,631,659.08, each by Eric Venker.

Key Figures

Proposed shares to be sold: 200,000 shares Aggregate value of proposed sale: 6,989,924.05 Shares sold 05/22/2026: 200,000 shares +3 more

6 metrics

Proposed shares to be sold 200,000 shares Common shares proposed for sale with expected sale date 07/27/2026

Aggregate value of proposed sale 6,989,924.05 Reported value associated with 200,000 common shares to be sold

Shares sold 05/22/2026 200,000 shares Common shares sold by Eric Venker on 05/22/2026

Aggregate value on 05/22/2026 6,054,730.92 Reported aggregate value for 200,000 shares sold on 05/22/2026

Shares sold 06/24/2026 200,000 shares Common shares sold by Eric Venker on 06/24/2026

Aggregate value on 06/24/2026 6,631,659.08 Reported aggregate value for 200,000 shares sold on 06/24/2026

Key Terms

Form 144, Options Exercise, Common Shares, Securities Sold During The Past 3 Months

4 terms

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Options Exercise financial

"Options Exercise - Grant Date 04/20/2022"

Exercising an option is the act of using a contract that gives you the right to buy or sell a specific stock at a set price. For investors, the decision to exercise matters because it turns a paper right into an actual trade — it can create immediate profit or loss, change how many shares are outstanding (which can dilute ownership), affect cash the investor must pay or receive, and trigger tax consequences, much like deciding to redeem a coupon for a fixed-price purchase.

Common Shares financial

"Common Shares | 07/27/2026 | Options Exercise"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

Securities Sold During The Past 3 Months regulatory

"144: Securities Sold During The Past 3 Months"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Roivant Sciences (ROIV) report in this Form 144 notice?

Roivant Sciences is reported as the issuer for a planned sale of 200,000 common shares by affiliate Eric Venker, expected to be issued from an option exercise granted on 04/20/2022 and proposed to be sold on 07/27/2026 on NASDAQ.

How many Roivant Sciences (ROIV) shares are proposed to be sold?

The filing reports a proposed sale of 200,000 common shares of Roivant Sciences. These shares are tied to an options exercise with a grant date of 04/20/2022, with a proposed sale date of 07/27/2026 on NASDAQ.

What prior Roivant Sciences (ROIV) share sales are disclosed for the last 3 months?

The notice lists two past sales by Eric Venker: 200,000 common shares on 05/22/2026 for 6,054,730.92 and 200,000 common shares on 06/24/2026 for 6,631,659.08, both involving Roivant Sciences common shares.

Who is the selling security holder in the Roivant Sciences (ROIV) Form 144?

The selling security holder is identified as Eric Venker, care of Roivant Sciences Ltd., 7th Floor, 50 Broadway, London. He is associated with both the proposed 200,000-share sale and the two prior 200,000-share sales disclosed.

What is the role of options in the planned Roivant Sciences (ROIV) share sale?

The planned sale of 200,000 common shares is linked to an “Options Exercise – Grant Date 04/20/2022”. This indicates the seller expects to receive the shares through exercising options granted on that date before selling them.

On which market is the planned Roivant Sciences (ROIV) sale expected to occur?

The proposed sale of 200,000 Roivant Sciences common shares is associated with trading on NASDAQ. Settlement is indicated as by wire, and the proposed date for the transaction is 07/27/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/27/2026 - 04:16 PM Accepted by SEC EDGAR 07/27/2026 - 04:16 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001801917
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Roivant Sciences Ltd.
SEC File Number	001-40782
Address of Issuer	7TH FLOOR, 50 BROADWAY LONDON UNITED KINGDOM SW1H 0DB
Phone	441-295-5950
Name of Person for Whose Account the Securities are To Be Sold	Venker Eric
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Rockefeller Financial LLC 45 Rockefeller Plaza Floor 5 New York NY 10111	200000	6989924.05	719270385	07/27/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Shares	07/27/2026	Options Exercise - Grant Date 04/20/2022	Roivant Sciences Ltd.			200000	07/27/2026	Wire

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H0DB	Common Shares	05/22/2026	200000	6054730.92
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H0DB	Common Shares	06/24/2026	200000	6631659.08

144: Remarks and Signature

Remarks	The shares reported on this Form 144 will be sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 03/28/2025.
Date of Notice	07/27/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/28/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Carmen Zamores as a duly authorized representative of National Financial Services LLC, as attorney-in-fact for Venker Eric
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)